Background Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed.
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on …

Summary mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time;
however, there are limited data on the impact of durability of immune responses on …

Neutralizing antibody responses gradually wane against several variants of concern (VOCs)
after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Abstract B. 1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant most resistant to antibody neutralization. We demonstrate how the dose and number …

INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy.
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate …

Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …

Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its …